MaxCyte (MXCT) Q4 2025 earnings review
Core Revenue Collapse Overshadows Cost Cuts and SPL Progress
MaxCyte ended 2025 on a difficult note. Q4 total revenue fell 16% YoY to $7.3 million, dragged down by a staggering 45% collapse in Processing Assemblies (PAs) and consumables. Management attributed this to a 15% reduction in purchases and leases from their largest SPL customer. While a swift Q3 restructuring successfully reduced operating expenses and narrowed the Q4 net loss to $9.6 million, the 2026 guidance reveals ongoing weakness. Management expects Core Revenue to decelerate further to $25-$27 million in 2026, introducing a $4 million headwind. The bright spot remains the maturation of the SPL portfolio and expected growth from commercial royalties, but it is currently insufficient to offset near-term core headwinds.
🐂 Bull Case
The 34% workforce reduction initiated in Q3 is taking effect. Q4 operating expenses dropped sharply to $16.9M from $19.3M YoY, reducing annual cash burn and leaving $155.6M on the balance sheet—plenty of runway.
MaxCyte expects up to four therapies in Phase III by the end of 2026. Royalties from Vertex's CASGEVY and other milestones are projected to drive SPL revenue up to $5M in 2026.
🐻 Bear Case
A manufacturing reorganization and inventory management by the company's largest SPL client essentially wiped out core growth, driving a 45% YoY drop in Q4 PAs and creating a $4M headwind for 2026.
Core revenue went from 8% growth in Q2 to consecutive 20%+ declines in H2. The 2026 guidance implies another ~12% contraction, proving the current weakness is structural, not a one-quarter blip.
⚖️ Verdict: 🔴
Bearish. The aggressive cost-cutting ensures survival, and the SPL pipeline has genuine long-term value. However, the unexpected deterioration of the core consumables business and weak 2026 guidance indicate that MaxCyte's revenue base has not yet found a floor.
Key Themes
Collapse in Processing Assemblies (PAs)
The most alarming metric in the Q4 report is the drastic deceleration in PAs and consumables revenue. It fell 45% YoY to $2.31M. Because PAs represent recurring, high-margin revenue from ongoing clinical programs, this sharp drop heavily pressures gross margins and reflects deeper pipeline rationalization or severe inventory corrections at key partners.
Operational Discipline Yields Immediate Results
Management's painful but necessary Q3 restructuring (a 34% workforce reduction) showed tangible results in Q4. Total operating expenses were $16.9M, down from $19.3M a year ago and $21.2M in H1 2025. This discipline limits cash burn, allowing the company to project an ending 2026 cash balance of at least $136M, ensuring they do not need to dilute shareholders in a depressed market.
Maturation of the SPL Portfolio
Despite core headwinds, the strategic long-term driver—the Strategic Platform License (SPL) model—is stable. The company ended 2025 with 32 SPL agreements (up from 28 at the end of 2024), including 13 active clinical programs. Management explicitly noted they expect to support up to four therapies in Phase III by the end of 2026, which accelerates the timeline for high-value commercial milestones and royalties.
Margin Pressure Due to Volume and Mix
Non-GAAP adjusted gross margin compressed to 78% in Q4 from 84% a year ago. This deceleration is directly tied to the mix shift away from highly profitable PAs and licenses towards lower-tier instruments and Assay Services. If PA volumes do not recover, long-term margin targets will remain under pressure.
Expanding the TAM with ExPERT DTx and SeQure DX
Management is actively trying to diversify away from its concentrated client base. The newly launched ExPERT DTx discovery platform aims to capture early-stage research revenue. Meanwhile, the SeQure DX assay services (which generated $0.8M in FY25) expands MaxCyte's capabilities into gene editing risk assessment. While early, these represent necessary pivots toward an end-to-end platform.
Other KPIs
Accelerating. Instrument sales grew 13% YoY, bucking the broader core revenue decline. This suggests that despite CapEx hesitancy in the broader biotech market, new customers and international placements are still adopting the hardware, even if usage (consumables) at existing top accounts is lagging.
Stable. Down from $190.3M at the end of 2024. The cash burn of ~$35M for the year was largely expected, and with the recent restructuring bringing down quarterly OpEx, the balance sheet remains a fortress that provides multi-year runway without financing risk.
Guidance
Decelerating. The midpoint of $31.0M implies a 6% decline from FY25's $33.0M. This marks a continued top-line contraction and reflects a cautious outlook on biotech funding and customer program rationalization.
Decelerating. The midpoint implies a roughly 12% YoY decline from $29.6M in 2025. Management explicitly cited approximately $4 million in core revenue headwinds from select SPL customers that will persist through the first half of 2026.
Accelerating. Improving from $3.4M in FY25. This includes approximately $3M from milestone payments and $2M from commercial royalties (driven heavily by CASGEVY), confirming that the long-term royalty model is functioning, even if slower than bulls originally hoped.
Implies a maximum cash burn of ~$19.6M for the year. This is a dramatic improvement over the ~$35M burned in 2025 and highlights the effectiveness of the Q3 headcount reductions.
Key Questions
Visibility into Largest Customer
The $4M core revenue headwind in 2026 is largely attributed to your largest SPL customer. Do you have firm commitments or minimum volume guarantees that provide a definitive floor for this customer's revenue in the second half of 2026?
Margin Profile Rebound
With non-GAAP gross margins compressing to 78% in Q4, and higher-margin PA revenue expected to remain depressed through H1 2026, what are the realistic expectations for gross margin stabilization in the upcoming fiscal year?
ExPERT DTx Launch Trajectory
The ExPERT DTx discovery platform launched last month. What are the early adoption metrics, and how much of the 2026 Core Revenue guidance depends on the successful ramp of this new product line?